Related Experiment Video

Updated: Jul 6, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

W Zhao1, Y H Gu, R Song

  • 1State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Leukemia
|March 14, 2008
PubMed

Insights

Sorafenib, a cancer drug, inhibits T-cell proliferation and activation. This drug may cause immunosuppression by inducing T-cell apoptosis and targeting LCK, impacting the immune response.

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Sorafenib is a multi-kinase inhibitor used for metastatic renal cancer.
  • Its effects on the human immune system, particularly T cells, are not well understood.

Purpose of the Study:

  • To investigate the impact of sorafenib on human T-cell proliferation and activation.
  • To evaluate sorafenib's effects on T-cell-mediated immune responses in a mouse model.

Main Methods:

  • In vitro studies using primary human T cells.
  • In vivo studies assessing contact dermatitis in mice.
  • Analysis of T-cell proliferation, apoptosis, cell cycle, surface marker expression (CD25, CD69), cytokine production (interleukin-2), and LCK phosphorylation.

Main Results:

  • Sorafenib inhibited human T-cell proliferation in a dose-dependent manner, with irreversible effects at concentrations above 10 microM.
  • Sorafenib induced T-cell apoptosis, G(0)/G(1) phase arrest, and suppressed CD25/CD69 expression and interleukin-2 production.
  • In vivo, sorafenib significantly reduced contact dermatitis in mice, indicating an impaired T-cell-mediated immune response.

Conclusions:

  • Sorafenib exerts significant immunosuppressive effects by inhibiting T-cell proliferation and activation.
  • The drug induces T-cell apoptosis and targets LCK, potentially leading to a loss of T-cell immune response in cancer patients.
  • These findings highlight a potential risk of immunosuppression associated with sorafenib treatment.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...